Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: November 30, 2009
Last updated: October 4, 2010
Last verified: October 2010

Primary Objective:

To evaluate the efficacy and safety of the use of Stilnox CR in Mexican patients with chronic insomnia at the prescription conditions of daily practice

Secondary Objective:

To evaluate the satisfaction of the patient with chronic insomnia with Stilnox CR over an as needed basis.

Condition Intervention Phase
Sleep Disorders
Drug: ZOLPIDEM SL800750
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) Administered on as Needed Basis in Patients With Chronic insomNIA

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Improvement of the Clinical Global Impression (CGI) score [ Time Frame: At day 84 (visit 5) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Illness severity and average change during the study [ Time Frame: At day 1 (baseline), day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5) ] [ Designated as safety issue: No ]
  • Pittsburgh Sleep Quality Index (PSQI) score [ Time Frame: At day 1 (baseline), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5) ] [ Designated as safety issue: No ]
  • Patient satisfaction questionnaire [ Time Frame: At day 84 (visit 5) ] [ Designated as safety issue: No ]
  • Safety evaluation via Adverse events reported [ Time Frame: At day 14 (visit 2), day 28 (visit 3), day 56 (visit 4) and day 84 (visit 5) ] [ Designated as safety issue: Yes ]

Enrollment: 135
Study Start Date: November 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Zolpidem 12.5mg tablet at bed time during 12 weeks
Drug: ZOLPIDEM SL800750

Pharmaceutical form: Zopidem 12.5 mg tablets

Route of administration: Oral

Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Primary insomnia diagnosis (difficulty for initiating sleep, or maintaining sleep to wake up to early in the morning, or to present a restless sleep) which causes clinically significant disturbances in the areas of social, work functioning or other important areas

Exclusion criteria:

  • Serious, severe and/or acute respiratory impairment
  • Severe liver impairment
  • Hypersensitivity to the formulation components or to some of its active metabolites
  • Pregnant or breast-feeding women Patients with important associated disorders in SNC and specially psychotic disorders
  • Patients with the probability of using alcoholic beverages concomitantly (as a precaution measure)
  • Chronic use of benzodiazepines

Moreover, in order to follow the international regulations in terms of the use and handling of hypnotic compounds, and to guarantee the appropriate study performance, no patients with one or more of the following characteristics should be included:

  • Patients who cannot comply to follow-up
  • Patients who have any drug abuse problem
  • Individuals who work changing night shifts or with pathological snoring
  • Presence (or suspicion) of sleep apnea, periodical legs movements or restless legs syndrome

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01024192

Sanofi-Aventis Administrative Office
Col. Coyoacan, Mexico
Sponsors and Collaborators
Study Director: Medical Affairs Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT01024192     History of Changes
Other Study ID Numbers: ZOLPI_L_04134 
Study First Received: November 30, 2009
Last Updated: October 4, 2010
Health Authority: Mexico: Ethics Committee

Additional relevant MeSH terms:
Mental Disorders
Nervous System Diseases
Sleep Wake Disorders
Central Nervous System Depressants
GABA Agents
GABA Agonists
GABA-A Receptor Agonists
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016